Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Two-year Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity

Trial Profile

Two-year Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 May 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Acronyms STEP 5
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 26 May 2020 All the trials are ongoing, and results will be available in 2020, except for those from the long term WM trial (STEP 5), which finishes in 2021 as per trial design published in the Obesity (Silver Spring, Md.)
    • 26 May 2020 Key elements of STEP 1 to 5 trial published in the Obesity (Silver Spring, Md.)
    • 04 Mar 2019 Status changed from recruiting to active, no longer recruiting.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top